diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM7696diaendo-7696Research ArticleДоказательная диабетологияEvidence Based DiabetologyРезультаты исследования ADVANCE и постинтервенционной наблюдательной программы ADVANCE-ON: изменились ли наши представления о взаимосвязи гликемического фактора и риска сосудистых осложнений у больных сахарным диабетом 2 типа?Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?ШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna

доктор медицинских нак, профессор, член.-корр.РАМН, директор института Диабета, заведующая кафедрой диабетологии и эндокринологии Педиатрического факультета

MD, PhD, Professor, correspondence fellow of the Russian Academy of Sciences

yushkha@gmail.comХалимовЮрий ШавкатовичKhalimovYuriy Shavkatovich

доктор медицинских наук, профессор, начальник кафедры военно-полевой терапии

MD, PhD, Professor

yushkha@gmail.comФГБУ Эндокринологический научный центр; ГБОУ ВПО Первый МГМУ им И.М. СеченоваРоссияEndocrinology Research Centre; Sechenov First Moscow State Medical UniversityRussian FederationФГБВОУ ВПО Военно-медицинская академия имени С.М. КироваРоссияMilitary medical academy of S.M. KirovRussian Federation201513112015184119124Copyright © Шестакова М.В., Халимов Ю.Ш., 20152015Шестакова М.В., Халимов Ю.Ш.Shestakova M.V., Khalimov Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7696

В статье представлен анализ результатов исследования ADVANCE и постинтервенционной программы ADVANCE-ON, посвященных оценке влияния интенсивного контроля гликемии на частоту микро- и макрососудистых событий у пациентов с сахарным диабетом 2 типа (СД2) и оценке долгосрочных результатов интенсивного контроля гликемии. Обсуждается динамика представлений о влиянии характера гликемического контроля на развитие риска сердечно-сосудистых осложнений. На основании анализа результатов исследований объясняется безопасность терапии гликлазидом МВ у пациентов с СД2 и высоким риском сердечно-сосудистых осложнений.

The results from the analysis of the ADVANCE trial and post-intervention program ADVANCE-ON are presented in this article. These studies are dedicated to study the effect of intensive glycemic control on the incidence of micro- and macrovascular events in patients with type 2 diabetes mellitus and evaluation of long-term results of intensive glycemic control. We discuss the progress of views on the impact of glycemic control on the development of cardiovascular complications. According to the analysis of the research results, gliclazide MR is safe in patients with type 2 diabetes at high risk for cardiovascular complications.

сахарный диабет 2 типаADVANCEADVANCE-ONпрепараты сульфонилмочевиныгликлазид МВtype 2 diabetesADVANCEADVANCE-ONdrugs sulfonylureasgliclazideReferencesNathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. doi: 10.2337/dc13-2112Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. doi: 10.2337/dc13-2112The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/NEJM199309303291401The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/NEJM199309303291401Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853. doi: 10.1016/S0140-6736(98)07019-6Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853. doi: 10.1016/S0140-6736(98)07019-6Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. doi: 10.1136/bmj.321.7258.405Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. doi: 10.1136/bmj.321.7258.405Bloomgarden ZT. Glycemic Control in Diabetes: A Tale of Three Studies. Diabetes Care. 2008;31(9):1913-1919. doi: 10.2337/dc08-zb09Bloomgarden ZT. Glycemic Control in Diabetes: A Tale of Three Studies. Diabetes Care. 2008;31(9):1913-1919. doi: 10.2337/dc08-zb09Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-2572. doi:10.1056/NEJMoa0802987Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-2572. doi:10.1056/NEJMoa0802987Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet.2007;370(9590):829-840. doi: 10.1016/S0140-6736(07)61303-8Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet.2007;370(9590):829-840. doi: 10.1016/S0140-6736(07)61303-8Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89(2):126-133. doi: 10.1016/j.diabres.2010.05.012Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89(2):126-133. doi: 10.1016/j.diabres.2010.05.012van Dieren S, Kengne AP, Chalmers J, et al. Intensification of medication and glycaemic control among patients with type 2 diabetes – the ADVANCE trial. Diabetes, Obesity and Metabolism. 2014;16(5):426-432. doi: 10.1111/dom.12238van Dieren S, Kengne AP, Chalmers J, et al. Intensification of medication and glycaemic control among patients with type 2 diabetes – the ADVANCE trial. Diabetes, Obesity and Metabolism. 2014;16(5):426-432. doi: 10.1111/dom.12238Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54(7):1608-1614. doi: 10.1007/s00125-011-2104-xStefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54(7):1608-1614. doi: 10.1007/s00125-011-2104-xZoungas S, de Galan BE, Ninomiya T, et al. Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068-2074. doi: 10.2337/dc09-0959Zoungas S, de Galan BE, Ninomiya T, et al. Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32(11):2068-2074. doi: 10.2337/dc09-0959Gæde P, Vedel P, Larsen N, et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med. 2003;348(5):383-393. doi: doi:10.1056/NEJMoa021778Gæde P, Vedel P, Larsen N, et al. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med. 2003;348(5):383-393. doi: doi:10.1056/NEJMoa021778Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: doi:10.1056/NEJMoa0806470Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: doi:10.1056/NEJMoa0806470Ceriello A. The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol. 2012;57(5-6):133-138. doi: 10.1016/j.vph.2012.05.005Ceriello A. The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol. 2012;57(5-6):133-138. doi: 10.1016/j.vph.2012.05.005Perkovic V, Verdon C, Ninomiya T, et al. The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLoS Medicine. 2008;5(10):e207. doi: 10.1371/journal.pmed.0050207Perkovic V, Verdon C, Ninomiya T, et al. The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLoS Medicine. 2008;5(10):e207. doi: 10.1371/journal.pmed.0050207Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: 10.1056/NEJMoa1407963Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-1406. doi: 10.1056/NEJMoa1407963

The authors declare that there are no conflicts of interest present.